Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
267 USD +3.18% Intraday chart for Madrigal Pharmaceuticals, Inc. +4.61% +15.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch RE
Madrigal commences $500 million public offering of common stock RE
North American Morning Briefing : Investors -2- DJ
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating MT
Madrigal Pharmaceuticals Gets Added Boost with Rezdiffra Nod From FDA, B. Riley Says MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating MT
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's... Our Logo
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating MT
Old demons return as tech takes a dive Our Logo
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155 MT
Wall St futures mixed as inflation woes weigh RE
Investors Turn Cautious Ahead of Next Week's Fed Meeting, Stifling US Equity Futures Pre-Bell MT
Top Premarket Gainers MT
Madrigal Shares Leap Premarket on First FDA NASH Green Light DJ
Futures nearly flat ahead of Fed meet next week RE
Madrigal Pharmaceuticals Gets FDA Approval for Liver Fibrosis Therapy MT
Transcript : Madrigal Pharmaceuticals, Inc. - Special Call
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA DJ
Chart Madrigal Pharmaceuticals, Inc.
More charts
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
267 USD
Average target price
394.5 USD
Spread / Average Target
+47.75%
Consensus
  1. Stock
  2. Equities
  3. Stock Madrigal Pharmaceuticals, Inc. - Nasdaq
  4. News Madrigal Pharmaceuticals, Inc.
  5. B. Riley Lowers Madrigal Pharmaceuticals' PT to $131 from $174 to Account for Lower Market Share of THR-B Drug Class, Keeps Buy Rating